NEREUS
Live / Applied — Statement of use — processing complete, to examiner (as of 29 Sept 2026)
What this means for you
Not registered yet, but its 15 Dec 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99548441
- Mark type
- Word mark
- Filed
- 15 Dec 2025
- Published for opposition
- 26 May 2026
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment and prevention of vomiting induced by motion
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prosecution history
- 29 Sept 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 15 Sept 2026 — USE AMENDMENT FILED
- 15 Sept 2026 — TEAS STATEMENT OF USE RECEIVED
- 21 Jul 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 May 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 May 2026 — PUBLISHED FOR OPPOSITION
- 20 May 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Apr 2026 — ASSIGNED TO EXAMINER
- 15 Dec 2025 — APPLICATION FILING RECEIPT MAILED
- 15 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 15 Dec 2025 — NEW APPLICATION ENTERED